Biomedical Engineering Reference
In-Depth Information
51. Strumberg D et al (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase
and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with
advanced refractory solid tumors. J Clin Oncol 23:965-972
52. Tan AR et al (2004) Evaluation of biologic end points and pharmacokinetics in patients with
metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor
tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090
53. Burris HA III et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of
lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor
tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol
23:5305-5313
54. Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med 362:2260-2270
55. Soulieres D et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth
factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous
cell cancer of the head and neck. J Clin Oncol 22:77-85
56. Buclin T et al (2011) Who is in charge of assessing therapeutic drug monitoring? The case
of imatinib. Lancet Oncol 12:9-11
57. van Erp NP et al (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat
Rev 35:692-706
58. Bouchet S et al (2010) Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treat-
ment of chronic myelogenous leukaemia: interests and limits. Therapie 65:213-218
59. Gambacorti-Passerini C et al (2000) Role of alpha1 acid glycoprotein in the in vivo resistance
of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst
92:1641-1650
60. le CP et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite
CGP74588. Cancer Chemother Pharmacol 53:313-323
61. Wang L et al (2008) Expression of the uptake drug transporter hOCT1 is an important clinical deter-
minant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258-264
62. Haouala A et al (2010) Cardiovascular drug interactions with tyrosine kinase inhibitors.
Cardiovasc Med 13:147-154
63. Haouala A et al (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasat-
inib, and nilotinib. Blood 117:e75-e87
64. Gambillara E et al (2005) Severe pustular eruption associated with imatinib and voriconazole
in a patient with chronic myeloid leukemia. Dermatology 211:363-365
65. Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid
leukemia. N Engl J Med 355:2408-2417
66. Takahashi N et al (2010) Correlation between imatinib pharmacokinetics and clinical response
in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther
88:809-813
67. Singh N et al (2009) Drug monitoring of imatinib levels in patients undergoing therapy for
chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur
J Clin Pharmacol 65:545-549
68. Awidi A et al (2010) Relationship of serum imatinib trough level and response in CML
patients: long term follow-up. Leuk Res 34:1573-1575
69. Faber E et al (2010) Imatinib dose escalation in two patients with chronic myeloid leukemia,
with low trough imatinib plasma levels measured at various intervals from the beginning of
therapy and with suboptimal treatment response, leads to the achievement of higher plasma
levels and major molecular response. Int J Hematol 91:897-902
70. Larson RA (2009) Therapeutic monitoring of drug plasma concentrations and improved
clinical outcomes in CML. Clin Adv Hematol Oncol 7:S3-S5
71. Kantarjian H et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-
positive ALL. N Engl J Med 354:2542-2551
72. Saglio G et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leuke-
mia. N Engl J Med 362:2251-2259
